TrialsgrambetaRCTs are beautiful

SONAR

2019

Study of Diabetic Nephropathy with Atrasentan

In 2,648 patients with type 2 diabetes and CKD selected for response, atrasentan reduced the composite of creatinine doubling or ESKD compared with placebo.

Result

Efficacy: Doubling of serum creatinine or ESKDHR 0.65 (95% CI 0.49-0.88) · P = 0.0047

Below 1 favours atrasentan, above 1 favours placebo.

Also reported: More fluid retention and oedema with atrasentan.

Original publication
Subtopic
Endothelin antagonists
Design
Double-blind RCT, enrichment (responder) design
Relevance
Supporting: context rather than must-know.
Source
Heerspink HJL, et al. Lancet. 2019;393(10184):1937-1947.doi 10.1016/S0140-6736(19)30772-X

Discussion & critique

Proof of concept for selective endothelin-A antagonism; the enrichment design limits generalisability.

Discussed in podcasts